White House nears deal to lower prices for weight loss drugs

The Trump administration is reportedly close to finalizing a deal with Eli Lilly and Novo Nordisk to significantly reduce the price of their blockbuster GLP-1 weight loss drugs, Zepbound and Wegovy, to as low as $149 per month for the lowest doses. In exchange, Medicare would expand coverage for these medications to certain beneficiaries, a move that could reshape the market for these high-demand drugs. This initiative, part of Trump's 'most favored nation' drug pricing push, represents a voluntary agreement that contrasts with the Inflation Reduction Act's negotiation framework, potentially impacting pharmaceutical companies' revenue streams and Medicare's drug expenditure.

Analysis

The Trump administration is reportedly nearing a deal with Eli Lilly and Novo Nordisk to significantly reduce the price of their blockbuster GLP-1 weight loss drugs, Zepbound and Wegovy, to as low as $149 per month for the lowest doses. This potential agreement, which would expand Medicare coverage for certain beneficiaries, represents a substantial price cut from current list prices exceeding $1,000 monthly, though the specific scope of the $149 price remains unclear. The general sentiment surrounding this news is moderately positive, yet the tone is speculative, reflecting the unconfirmed nature of the deal details.

This initiative aligns with former President Trump's "most favored nation" drug pricing strategy, emphasizing voluntary agreements over the Inflation Reduction Act's negotiation framework. While expanded Medicare coverage could significantly broaden market access for GLP-1s, the proposed price reduction has generated negative per-ticker sentiment for both Eli Lilly (-0.4) and Novo Nordisk (-0.4), indicating investor concern over potential revenue compression despite increased volume. This highlights a perceived trade-off between market penetration and profitability for pharmaceutical companies.

The article also notes that retailers like Costco and Walmart are already offering lower-cost options for cash payers, suggesting a broader market trend towards increased accessibility. The positive per-ticker sentiment for Costco (0.3) and Walmart (0.3) indicates that these retailers could benefit from increased prescription volumes if the deal drives broader adoption and accessibility of these high-demand medications. The ultimate impact hinges on the final terms and the extent of the $149 price application across different payer types.

Key Decisions for Investors

• Investors should closely monitor the finalization and specific terms of the reported deal, particularly whether the $149 price applies broadly or is limited to specific Medicare beneficiaries or cash payers, as this will dictate the revenue impact for LLY and NVO.
• Evaluate the potential long-term revenue implications for Eli Lilly and Novo Nordisk, as significant price reductions, even with expanded coverage, could compress margins on blockbuster drugs, warranting a re-evaluation of their growth projections.
• Observe how this voluntary agreement influences the broader drug pricing landscape and the future of the Inflation Reduction Act's negotiation process, as it signals a potential shift in regulatory approach under a future Trump administration.
• Consider the potential positive impact on retailers like Costco and Walmart, which are already facilitating access to these drugs, as increased accessibility and potentially lower prices could drive higher prescription volumes through their pharmacies.